BTK and B-cell chronic lymphocytic leukemia: Based on data showing a worse toxicity profile for ibrutinib and a black box warning for sudden cardiac deaths, international guidelines recommend the use of second generation BTK inhibitors over ibrutinib for patients with CLL [32].